Transparency log
Evidence & Policy Updates
ApprovedPA continuously monitors published clinical trials, society guidelines, and payer coverage policies. Every change to the evidence base and payer criteria used in generated letters is logged here.
Next scheduled review: ACC Annual Sessions (March 2027) · ADA Scientific Sessions (June 2027)
May 2026
ACC 2025 Expert Consensus Statements Added
Two new American College of Cardiology documents published in JACC 2025 have been incorporated into the evidence base used in all generated letters. The first — "2025 ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health" — explicitly supports anti-obesity pharmacotherapy as a first-line cardiovascular risk reduction strategy, without requiring step therapy failure. The second — "2025 ACC Scientific Statement on the Management of Obesity in Adults With Heart Failure" — directly supports GLP-1 receptor agonist use in obese patients with HFpEF, referencing STEP-HFpEF outcomes data.
Impact
Strengthens cardiovascular-indication appeals across all payers. The HF statement provides direct guideline support for appeals involving patients with heart failure, pairing with our existing STEP-HFpEF trial data.
May 2026
AACE 2025 Obesity Algorithm & 2026 T2DM Consensus Added
The American Association of Clinical Endocrinology published two updated consensus statements that supersede the AACE 2023 guidance previously cited. The 2025 obesity update (Endocr Pract, November 2025) affirms anti-obesity medications as primary therapy alongside lifestyle modification and explicitly states that step therapy requirements are not supported by clinical evidence. The 2026 T2DM consensus update (Endocr Pract, April 2026) designates GLP-1 receptor agonists as preferred agents in patients with obesity and T2DM given their cardiometabolic benefit profile.
Impact
Letters now cite the most current AACE guidance. Particularly relevant for Aetna and Cigna appeals, whose coverage criteria align closely with endocrinology society recommendations.
May 2026
SELECT Subgroup Analysis (Lancet 2025) Added
A prespecified subgroup analysis of the SELECT trial (Lancet, November 2025) confirmed that the cardiovascular benefit of semaglutide 2.4mg was consistent regardless of baseline BMI and degree of weight loss achieved during treatment. This directly addresses a common payer argument that CV benefit is weight-loss dependent and therefore requires evidence of prior weight loss attempts before approval.
Impact
Strengthens the rebuttal when payers deny on the basis that the patient has not demonstrated weight loss capacity. The CV benefit indication is independent of weight loss magnitude.
April 2026
Initial Evidence Base Established
ApprovedPA launched with a curated evidence base drawn from the landmark GLP-1 randomized controlled trials and current society guidelines. All citations are verified from published peer-reviewed sources and embedded directly — no dynamic retrieval — to ensure accuracy in every generated letter.
Impact
Baseline evidence supporting all current letter generation.